A Study to Assess the Effect of a Single Infusion of VAY736 on Disease Activity in Patients With Relapsing-remitting Multiple Sclerosis
Stopped The study recruitment was terminated based on strategic considerations after 8 patients were enrolled.
Conditions
- Relapse Remitting Multiple Sclerosis
Interventions
- DRUG: VAY736
- DRUG: Placebo
Sponsor
Novartis Pharmaceuticals